Allopathic medicine is a trade-off. You often trade one disease for another, often more serious, disease. Trade-off #1: “Aprotinin — a drug approved by the FDA, marketed internationally for the last 13 years, and given to an estimated one
million surgery patients to limit bleeding — has now been proven to double a patient’s risk of kidney failure, and increase the risk of heart attack, heart failure, and stroke.”
http://www.consumeraffairs.com/news04/2006/01/fda_aprotinin.html
